Cox model of overall mortality during days 100 to 365 after tisa-cel therapy
| Variable . | Category . | HR, 95% CI . | P value . |
|---|---|---|---|
| Infection history after tisa-cel infusion | No infections | 1.000 | .718 (3 df) |
| Infections during days 1-30 and 31-100 | 0.732 (0.292-1.838) | .507 | |
| Infection during days 1-30 only | 0.960 (0.566-1.629) | .880 | |
| Infection during days 31-100 only | 1.289 (0.725-2.291) | .386 | |
| Age, y | <6 | 1.000 | .003 (2 df) |
| 6-15 | 0.406 (0.233-0.709) | .002 | |
| >15 | 0.700 (0.419-1.170) | .174 | |
| Performance score (Lansky <16 years old; Karnofsky ≥16 years old) | 90-100 | 1.000 | <.001 (3 df) |
| 80 | 2.499 (1.610-3.880) | <.001 | |
| <80 | 1.781 (1.036-3.060) | .037 | |
| Missing | 1.645 (0.850-3.183) | .140 | |
| Disease status at tisa-cel infusion | CR | 1.000 | <.001 |
| Not in CR | 2.249 (1.491-3.393) | ||
| Any-grade CRS onset∗ | No | 1.000 | .020 |
| Yes | 1.536 (1.069-2.209) |
| Variable . | Category . | HR, 95% CI . | P value . |
|---|---|---|---|
| Infection history after tisa-cel infusion | No infections | 1.000 | .718 (3 df) |
| Infections during days 1-30 and 31-100 | 0.732 (0.292-1.838) | .507 | |
| Infection during days 1-30 only | 0.960 (0.566-1.629) | .880 | |
| Infection during days 31-100 only | 1.289 (0.725-2.291) | .386 | |
| Age, y | <6 | 1.000 | .003 (2 df) |
| 6-15 | 0.406 (0.233-0.709) | .002 | |
| >15 | 0.700 (0.419-1.170) | .174 | |
| Performance score (Lansky <16 years old; Karnofsky ≥16 years old) | 90-100 | 1.000 | <.001 (3 df) |
| 80 | 2.499 (1.610-3.880) | <.001 | |
| <80 | 1.781 (1.036-3.060) | .037 | |
| Missing | 1.645 (0.850-3.183) | .140 | |
| Disease status at tisa-cel infusion | CR | 1.000 | <.001 |
| Not in CR | 2.249 (1.491-3.393) | ||
| Any-grade CRS onset∗ | No | 1.000 | .020 |
| Yes | 1.536 (1.069-2.209) |
Analysis includes patients who are alive and free of subsequent HCT at day 100 landmark. Variables were chosen for inclusion by stepwise selection, with a P value of <.05 used as the criterion for inclusion. Infection history after CAR T-cell therapy was forced into the model. P values that are significant are indicated in bold.
CRS onset was treated as a time-dependent covariate.